Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
All currently available antipsychotic drugs are the dopamine D 2receptor antagonists and are capable of producing extrapyramidal side‐effects (EPS). Anticholinergic drugs are primarily used to treat EPS or prevent EPS induced by antipsychotics in the treatment of psychosis and schizophrenia. However, they can cause a variety of distressing peripheral side‐effects (e.g. dry mouth, urinary disturbances, and constipation) and central adverse effects (e.g. cognitive impairment, worsening of tardive dyskinesia, and delirium). Disturbances in cognitive abilities are cardinal features of schizophrenia from its earliest phases and account for much of the functional disability associated with the illness. It is likely that long‐term concomitant administration of anticholinergics exacerbates the underlying cognitive impairment in patients with schizophrenia and subsequently affects patients' quality of life. Thus, current treatment guidelines for schizophrenia generally do not recommend the prophylactic and long‐term use of anticholinergics. However, the high use of long‐term anticholinergic drugs with antipsychotics has been identified as an important issue in the treatment of schizophrenia in several countries. To assess the benefits and limits of anticholinergic use in psychosis and schizophrenia, this article will provide a brief review of the pharmacology and clinical profiles of anticholinergic drugs and will focus on their effects on cognitive function in schizophrenia, particularly during the course of the early phase of the illness. In addition, we will address the effects of discontinuation of anticholinergics on cognitive function in patients with schizophrenia and provide a strategy for adjunctive anticholinergic use in patients treated with long‐acting injectable antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783 · cited 1×
“SCHIZOPHRENIA IS A chronic and debilitating psychiatric illness with a worldwide prevalence of approximately 1%.(1) It is characterized by positive, negative, cognitive, and affective symptoms.”
BackgroundKeefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483 · cited 1×
“Recent advancements in the past years have allowed clinicians to address this issue by investigating individuals at clinical high risk (CHR) for psychosis.(67) This putatively prodromal psychotic phase is associated with an enhanced probability of developing the illness, mostly schizophrenia spectrum disorders,(68) as…”
BackgroundDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Predicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
Neurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130 · cited 1×
“20) across all cognitive domains, and the magnitude and pattern of these impairments approximate those documented in more chronic samples.(66) Accumulating evidence also suggests that for most schizophrenic patients, cognitive deficit is only slowly progressive after the first episode and some components of the defici…”
ResultMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 6×
“Anticholinergics should be used prudently and only as long as necessary to control EPS.7 If possible, clinicians should try to taper them gradually while monitoring for EPS.59 Patients with early psychosis are at higher risk for developing acute EPS, thus anticholinergics should not be administered irresponsibly witho…”
BackgroundInfluentialSelf-citationElevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
Cognitive Functioning in Prodromal Psychosis: A Meta-analysis
Fusar-Poli, P., Deste, G., Smieskova, R., Barlati, S., Yung, A. R., Howes, O., Stieglitz, R.-D., Vita, A., McGuire, P., & Borgwardt, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1592 · Cited by 691 · cited 2×
“At a meta-analytical level, CHR subjects were impaired relative to controls on tests of general intelligence, executive functions, verbal/visual memory, verbal fluency, attention and working memory, and social cognition.(86) Processing speed was also slower but the difference was not statistically significant.”
BackgroundMethodSubtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.002 · Cited by 286 · cited 4×
“M1, M3, and M5 receptors couple to Gq and activate phospholipase C, whereas M2 and M4 receptors couple to Gi/o and associated effecter systems, such as ion channels and adenylyl cyclase.(24,25,27) Dopamine, an inhibitory neurotransmitter in the caudate nucleus of the basal ganglia, is known to be in balance with choli…”
BackgroundInfluentialFusar-Poli, P., Howes, O. D., Allen, P., Broome, M., Valli, I., Asselin, M.-C., Grasby, P. M., & McGuire, P. K. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.77 · Cited by 234
Fusar-Poli, P., Howes, O. D., Allen, P., Broome, M., Valli, I., Asselin, M.-C., Montgomery, A. J., Grasby, P. M., & McGuire, P. (2011) · Molecular Psychiatry · doi:10.1038/mp.2009.108 · Cited by 207
Cited by
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
MacKenzie, N. E., Kowalchuk, C., Agarwal, S. M., Costa-Dookhan, K. A., Caravaggio, F., Gerretsen, P., Chintoh, A., Remington, G. J., Taylor, V. H., Müeller, D. J., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00622 · Cited by 205
“Of note, cognition improves when anticholinergic treatment is discontinued (36, 63).”
BackgroundECT in schizophrenia:a review of the evidence
Grover, S., Sahoo, S., Rabha, A., & Koirala, R. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.32 · Cited by 122
Pascal de Raykeer, R., Hoertel, N., Blanco, C., Lavaud, P., Kaladjian, A., Blumenstock, Y., Cuervo-Lombard, C.-V., Peyre, H., Lemogne, C., Limosin, F., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.05.063 · Cited by 35
Emotion regulation in adolescents with mental health problems
Henry, J. D., Castellini, J., Moses, E., & Scott, J. G. (2016) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2015.1100276 · Cited by 19
Metadata
- Authors
- Ogino, S., Miyamoto, S., Miyake, N., & Yamaguchi, N.
- Venue
- Psychiatry and Clinical Neurosciences
- Publisher
- Wiley
- Published
- 2013-09-19
- Volume
- 68
- Issue
- 1
- Pages
- 37-49
- ISSN
- 1323-1316 (ISSN-L)
- 1440-1819
- OpenAlex
- W1602753533
- Cited by
- 111
- References
- 16
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.